Avenue Biosciences
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.5Mattributed |
|---|---|
| Latest round | seed, $2.5M, 2024-10-01attributed |
| Founded | 2023 |
| Headquarters | Helsinki, Finland |
| Industry | bio |
| Stage | seed |
| Website | avenuebiosciences.com |
Machine-learning platform that engineers N-terminal signal peptides to boost protein expression yield in mammalian systems. Sold to therapeutic developers working on biologics, mRNA, biosimilars, antibodies, and vaccines. Spun out of University of Helsinki research with a $5.7M raise and BioTools Innovator selection.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-10-01 | seed | $2.5M | undisclosed |
Detected tech stack
Cloudflare, Unpkg, Google Tag Manager, cdnjs, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $2.5M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $2.5M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | avenuebiosciences.com, read 2026-05-05 |
| Description | self-reported | avenuebiosciences.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.